Molecular targeted therapy of BRAF-mutant colorectal cancer
M Ducreux, A Chamseddine… - … in medical oncology, 2019 - journals.sagepub.com
Over the past two decades, the molecular characterization of metastatic colorectal cancer
(mCRC) has been revolutionized by the routine implementation of RAS and BRAF tests. As …
(mCRC) has been revolutionized by the routine implementation of RAS and BRAF tests. As …
FOLFOXIRI plus bevacizumab as conversion therapy for patients with initially unresectable metastatic colorectal cancer: a systematic review and pooled analysis
G Tomasello, F Petrelli, M Ghidini, A Russo… - JAMA …, 2017 - jamanetwork.com
Importance The combination of fluorouracil, oxaliplatin, and irinotecan plus bevacizumab
(FOLFOXIRI-Bev) is an established and effective first-line chemotherapy regimen for …
(FOLFOXIRI-Bev) is an established and effective first-line chemotherapy regimen for …
[HTML][HTML] ESMO consensus guidelines for the management of patients with metastatic colorectal cancer
E Van Cutsem, A Cervantes, R Adam, A Sobrero… - Annals of …, 2016 - Elsevier
Colorectal cancer (CRC) is one of the most common malignancies in Western countries.
Over the last 20 years, and the last decade in particular, the clinical outcome for patients with …
Over the last 20 years, and the last decade in particular, the clinical outcome for patients with …
Upfront FOLFOXIRI plus bevacizumab and reintroduction after progression versus mFOLFOX6 plus bevacizumab followed by FOLFIRI plus bevacizumab in the …
C Cremolini, C Antoniotti, D Rossini, S Lonardi… - The Lancet …, 2020 - thelancet.com
Background The triplet FOLFOXIRI (fluorouracil, leucovorin, oxaliplatin, and irinotecan) plus
bevacizumab showed improved outcomes for patients with metastatic colorectal cancer …
bevacizumab showed improved outcomes for patients with metastatic colorectal cancer …
FOLFOXIRI plus bevacizumab versus FOLFIRI plus bevacizumab as first-line treatment of patients with metastatic colorectal cancer: updated overall survival and …
C Cremolini, F Loupakis, C Antoniotti, C Lupi… - The Lancet …, 2015 - thelancet.com
Background In the TRIBE study, FOLFOXIRI (fluorouracil, leucovorin, oxaliplatin, and
irinotecan) plus bevacizumab significantly improved progression-free survival of patients …
irinotecan) plus bevacizumab significantly improved progression-free survival of patients …
[HTML][HTML] Initial therapy with FOLFOXIRI and bevacizumab for metastatic colorectal cancer
F Loupakis, C Cremolini, G Masi… - … England Journal of …, 2014 - Mass Medical Soc
Background A fluoropyrimidine plus irinotecan or oxaliplatin, combined with bevacizumab (a
monoclonal antibody against vascular endothelial growth factor), is standard first-line …
monoclonal antibody against vascular endothelial growth factor), is standard first-line …
[HTML][HTML] ESMO Consensus Guidelines for management of patients with colon and rectal cancer. a personalized approach to clinical decision making
HJ Schmoll, E Van Cutsem, A Stein, V Valentini… - Annals of oncology, 2012 - Elsevier
Colorectal cancer (CRC) is the most common tumour type in both sexes combined in
Western countries. Although screening programmes including the implementation of faecal …
Western countries. Although screening programmes including the implementation of faecal …
[HTML][HTML] Bevacizumab plus mFOLFOX-6 or FOLFOXIRI in patients with initially unresectable liver metastases from colorectal cancer: the OLIVIA multinational …
T Gruenberger, J Bridgewater, I Chau, PG Alfonso… - Annals of …, 2015 - Elsevier
ABSTRACT OLIVIA, a multinational phase II study, suggests that bevacizumab plus
FOLFOXIRI improves outcomes, including response rates, resection rates, and progression …
FOLFOXIRI improves outcomes, including response rates, resection rates, and progression …
The oncosurgery approach to managing liver metastases from colorectal cancer: a multidisciplinary international consensus
R Adam, A De Gramont, J Figueras, A Guthrie… - The …, 2012 - academic.oup.com
An international panel of multidisciplinary experts convened to develop recommendations
for the management of patients with liver metastases from colorectal cancer (CRC). The aim …
for the management of patients with liver metastases from colorectal cancer (CRC). The aim …
Treatment of colorectal liver metastases in Germany: a ten-year population-based analysis of 5772 cases of primary colorectal adenocarcinoma
C Hackl, P Neumann, M Gerken, M Loss… - BMC cancer, 2014 - Springer
Background Purpose of this study was to analyse the surgical management and long-term
clinical outcome of patients diagnosed with colorectal liver metastases (CLM) over a period …
clinical outcome of patients diagnosed with colorectal liver metastases (CLM) over a period …